EGFR and non-small cell lung carcinoma: The largest study of this kind was the ImmunoTarget multicentric worldwide retrospective study [83], which gathered 125 EGFR, 43 BRAF, 36 MET, 29 HER2, 23 ALK, 16 RET, and 7 ROS1 NSCLC patients treated with anti-PD1 (92%) or anti-PD-L1, mostly in second- (42%), third- (26%) or later treatment lines (27%).